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Journal of Hepatology 50 (2009) 273–280The association of HBV core promoter double mutations (A1762T
and G1764A) with viral load diﬀers between HBeAg positive and
anti-HBe positive individuals: A longitudinal analysisq
Zhong-Liao Fang1,3, Caroline A Sabin2, Bai-Qing Dong3, Shao-Chao Wei4,
Qin-Yan Chen3, Kong-Xiong Fang4, Jin-Ye Yang3, Xue-Yan Wang3, Tim J. Harrison1,*
1Division of Medicine, UCL Medical School, Windeyer Building, Cleveland Street, London W1T 4JF, UK
2Research Department of Infection and Population Health, Division of Population Health, UCL Medical School, Royal Free Campus,
Rowland Hill Street, London NW3 2PF, UK
3Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Jin Zhou Road, Nanning, Guangxi, PR China
4Sanitary and Antiepidemic Station of Long An, ChengXi Rd, Cheng Xiang Town, Long An, Guangxi, PR ChinaBackground/Aims:Although there have been a few reports regarding the eﬀect of basal core promoter (BCP) double
mutations (A1762T and G1764A) on hepatitis B viral loads, the association remains uncertain. We aim to determine
the association after controlling for HBeAg – a strong confounding factor.
Methods:We selected randomly 190 individuals from a Chinese cohort of 2258 subjects for cross-sectional analysis and
56 of the 190 for longitudinal analysis of viral loads.
Results: In multivariable analysis of the cross-sectional data, BCP double mutations are signiﬁcantly associated with
lower viral loads in HBeAg positive subjects but no diﬀerence was found in anti-HBe positive subjects. Triple mutations
at nucleotide (nt) 1753, 1762 and 1764 and mutations between nt 1809 and 1817, precore stop mutation (nt 1896) and geno-
type are not associated with viral loads in either HBeAg or anti-HBe positive subjects. Analysis of the longitudinal data
yielded similar results to the cross-sectional data. Viral loads diﬀer signiﬁcantly between individuals infected with wild-type
and BCP double mutations prior to HBeAg seroconversion but this diﬀerence is lost after seroconversion.
Conclusions:BCP double mutations are associated with lower viral loads in HBeAg positive individuals but have no
eﬀect on the viral loads of anti-HBe positive individuals.
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Hepatitis B virus (HBV) has a 3.2 kb circular DNA
genome containing four partially overlapping open
reading frames (ORFs): C, encoding the nucleocapsid
(core) protein (HBcAg) and secreted e antigen (HBeAg);
P, the polymerase protein (Pol); S, the envelope pro-
teins; and X, a transcriptional trans-activator protein.
The core promoter located at nucleotides (nt) 1591–
1822 plays a central role in virus replication, directing
the synthesis of the pregenomic RNA, which, as wellPublished by Elsevier B.V. All rights reserved.
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HBcAg and Pol, and the precore RNA, which encodes
HBeAg [1]. The basal core promoter (BCP) has been
mapped to nt 1744–1804 [2].
The lack of proof-reading during reverse
transcription of the pregenomic RNA favours the devel-
opment of sequence variants during long-term HBV rep-
lication [3]. One of the most critical changes is the
appearance of double mutations at nt 1762 (A–T) and
1764 (G–A) in the BCP. The mutations were ﬁrst
reported by Okamoto et al. who suggested that they
might arrest the transcription of the precore RNA but
not seriously aﬀect that of the pregenomic RNA [4].
However, others suggested that these mutations seem
to be insuﬃcient to generate a HBeAg-negative pheno-
type [5] but may suppress the expression of HBeAg [6].
Subsequently, studies involving transfection of human
hepatoma cell lines and analysis of clinical samples
showed that these double mutations suppress, but do
not abolish, the synthesis of HBeAg and may also and
increase HBV DNA replication [2,7,8].
However, other reports do not support the
conclusion that BCP double mutations increase virus
replication, in that the BCP double mutations seem to
have no eﬀect on viral load [9–12] or even may be asso-
ciated with lower serum HBV DNA concentrations [13].
Furthermore, others found in transfection studies that
core promoter mutations other than those at nt 1762/
1764 seem to upregulate viral DNA replication [14,15].
Therefore, the eﬀect of the BCP double mutations on
viral loads remains uncertain.
HBeAg has been used as a marker of infectivity and
active virus replication in HBsAg-positive individuals
[16,17]. Seroconversion from HBeAg to anti-HBe, either
spontaneous or after antiviral therapy, usually results in
lower viral loads, this decline occurring usually up to 12
months before seroconversion [18]. Furthermore,
because of the complexity of the host immune system,
viral loads may ﬂuctuate over time [19]. Therefore, a sin-
gle measurement, or several measurements made around
the time of clearance of HBeAg, may not give a clear
view of the eﬀect of BCP double mutations on viral
loads. In this study, taking the advantage of our Chinese
cohort [20], we have carried out a cross-sectional analy-
sis to determine the association of BCP double muta-
tions and viral loads and a 3 year-longitudinal analysis
to test this association further.2. Study subjects and methods
2.1. The Long An cohort
In order to determine the value of screening carriers of hepatitis B
surface antigen (HBsAg) for virus with BCP double mutations as a
marker of an extremely high risk of developing HCC, a cohort of 2258hepatitis B surface antigen positive subjects aged 30–55 was recruited
in Guangxi, China. Written informed consent was obtained from each
individual. The study protocol conformed to the ethical guidelines of
the 1975 declaration of Helsinki and has been approved by the Guangxi
Institutional Review Board and the UCL Committee on the Ethics of
Non-NHS Human Research (Project no. 0042/001) [20].
From 1st March, 2004, the Chinese study team travelled to 128
villages in 12 townships of Long An county to visit agricultural work-
ers aged 30–55 for a 3 ml sample of blood by venepuncture for screen-
ing for HBsAg. All samples were tested for HBsAg and those positive
were tested in China for HBV DNA using nested PCR. We also
detected and excluded those positive for anti-HCV or alpha-fetopro-
tein (AFP) to eliminate the confounding eﬀect of HCV infection on
the incidence of HCC and pre-existing HCC. We started to follow
up our study subjects from 1st July, 2004. Each study subject com-
pleted a one-page questionnaire at the ﬁrst visit and provided a serum
sample every six months for the assessment of virological parameters
and AFP concentrations and was monitored for HCC by ultrasonog-
raphy (US).
2.2. Study subjects
2.2.1. Cross-sectional analysis
We selected randomly approximately 25 subjects within each of
eight sub-groups deﬁned by the various combinations of sex (male or
female), HBV status (HBeAg positive or anti-HBe positive) and BCP
sequence (wild-type or 1762/1762 double mutations) (Table 1) [20].
2.2.2. Longitudinal analysis
From these eight groups, we selected 58 study subjects for
longitudinal analysis. Eligible subjects were those who did not convert
from HBeAg to anti-HBe or from anti-HBe to HBeAg, whose HBV
sequences remained stable at nt 1762, 1764 and 1896 over the 3 years,
and for whom additional samples were available at each of three time
points (12, 24 and 36 months). We also selected subjects for the anal-
ysis of occurrences of seroconversion and sequence evolution, and the
association of these events with viral loads, including 10 individuals
with evolution from wild-type BCP to double mutations but without
HBeAg seroconversion and 17 individuals with clearance of HBeAg
without evolution of the BCP. No subject received antiviral or immu-
nosuppressive therapy during the 3-year period.
2.3. Serological testing
Sera were tested for HBsAg, HBeAg/anti-HBe using enzyme
immunoassays (Zhong Shan Biological Technology Company,
Limited, Guangzhou, China). Alanine aminotransferase (ALT) levels
were determined using a Reitman kit (Sichuan Mike Scientiﬁc
Technology Company, Limited, Chengdu, China).
2.4. Nested PCR for HBV DNA and nucleotide
sequencing
DNAwas extracted from 85 ll serum by pronase digestion followed
by phenol/chloroform extraction. For nested PCRof the core promoter,
ﬁrst roundPCRwas carriedout in a 50 ll reactionusingprimersB935 (nt
1240–1260, 50-GAAGGTTTGTGGCTCCTCTG-30) and MDC1 (nt
2304–2324, 50-TTGATAAGATAGGGGCATTTG-30), with 5 min hot
start followed by 30 cycles of 94 C for 30 s, 50 C for 30 s, and 72 C
for 90 s. Second round PCR was carried out on 5 ll of the ﬁrst round
product in a 50 ll reaction using primers CPRF1 (nt 1678–1695,
50-CAATGTCAACGACCGACC-30) and CPRR1 (nt 1928–1948,
50-GAGTAACTCCACAGTAGCTCC-30), with 5 min hot start
followed by 30 cycles of 94 C for 30 s, 55 C for 30 s, and 72 C for 30 s.
For nested PCR of the surface region, ﬁrst round PCR was carried
out in a 50 ll reaction using primers LSOB1 (nt 2739–2762,
50-GGCATTATTTGCATACCCTTTGG-30) and P2 [21] with 5 min
hot start followed by 30 cycles of 94 C for 30 s, 50 C for 30 s, and
72 C for 90 s. Second round PCR was carried out on 5 ll of the ﬁrst
round products in a 50 ll reaction using primers SSEQ5 (226–246,
Table 1
HBV core promoter mutations and HBeAg status and viral loads.
Groups No. Agea Genotypeb
(B/C/O/U)
Triple
mutation
(T1753V)
Triple
mutation
(C1766T)
Quadruple
mutation
(T1753V/
C1766T)
Mutation
(nt 1809–1817)
Precore stop
mutation
Viral loads
Median (range)
Male
HBeAg
1762/1764:
Wild-type
23 34.9 ± 6.0 1/14/1/7 0 0 0 0 1 4.3  108 (3.0  106, 9.0  109)
1762/1764:
mutant
25 36.4 ± 5.7 0/19/0/6 8 0 0 1 0 2.2  107 (3.9  105, 3.6  108)
anti-HBe
1762/1764:
Wild-type
24 40.5 ± 6.2 8/11/0/4 0 0 0 4 13 4.6  104 (1.9  102, 1.9  108)
1762/1764:
mutant
26 38.2 ± 6.0 4/19/0/3 13 2 1 4 7 1.6  105 (2.7  103, 2.0  109)
Female
HBeAg
1762/1764:
Wild-type
25 34.8 ± 6.0 1/18/0/6 0 0 0 2 1 2.6  108 (5.5  105, 1.6  109)
1762/1764:
mutant
18 37.8 ± 5.9 0/17/0/1 5 0 0 1 0 5.6  107 (2.2  104, 6.8  108)
anti-HBe
1762/1764:
Wild-type
25 43.8 ± 6.9 9/12/1/3 0 0 0 6 20 1.5  105 (6.9  102, 4.2  107)
1762/1764:
mutant
24 42.1 ± 7.1 0/21/1/1 15 1 1 4 11 8.9  104 (4.9  102, 1.9  108)
a Ages are means ± standard deviation.
b B and C: genotypes B and C; O: other genotypes, such genotype A or D; U: undetermined genotype using the current programme.
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1188, 50-AGCAAACACTTGGCATAGGC-30) and the same ampliﬁ-
cation protocol as ﬁrst round.
Products from the second rounds were conﬁrmed by agarose gel
electrophoresis and then puriﬁed using the GenEluteTM PCR Clean-
up Kit (Sigma, St. Louis MO, USA) according to the manufacturer’s
instructions. Cycle sequencing was carried out directly on both strands
using 2 ll puriﬁed amplicon DNA and primer LSBI1 or ADELN (nt
432–453, 50-TAGTCCAGAAGAACCAACAAG30) and a BigDye
Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s instructions.
2.5. Measurement of viral loads
Viral load measurements were carried out as described by Garson
et al. [22]. Brieﬂy, HBV DNA was extracted from serum samples using
a Qiagen BioRobot 9604 and QIAamp96 Virus Kit reagents (Qiagen,
Hilden, Germany). Viral DNA was ampliﬁed and quantiﬁed in an ABI
Prism 7000 sequence detection system (Applied Biosystems, Foster
City, CA, USA) using HBV primers and a dual labelled TaqMan
probe as described.
2.6. HBV genotyping
HBV genotyping were determined using HBV S gene sequences
above and the programmes STAR (http://www.vgb.ucl.ac.uk/
starn.shtml) [23] and the NCBI Genotyping Tool (http://
www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi).
2.7. Statistical methods
For all analyses, a logarithmic transformation was applied to all
viral load measurements prior to analysis to achieve an approximately
normal distribution.2.7.1. Cross-sectional analysis
Unadjusted comparisons between those with and without the BCP
mutations were performed using unpaired t-tests on the logged values;
multiple linear regression analysis was then used to assess whether any
diﬀerences remained signiﬁcant after adjusting for HBeAg status and
other factors (age, sex and HBV genotype). Formal tests of interaction
were performed to determine whether any associations noted diﬀered
quantitatively or qualitatively between those who were HBeAg nega-
tive and those who were HBeAg positive.
2.7.2. Longitudinal analysis
In the longitudinal analyses, viral loads at 12, 24 and 36 months,
and pre- and post-HBeAg seroconversion were summarised using
medians and ranges; logged viral loads were then compared in those
with and without the double mutations at each timepoint using
unpaired t-tests. For the group who experienced HBeAg
seroconversion, assessment of the signiﬁcance of changes in viral load
from pre- to post-seroconversion, overall and within each subgroup,
was performed using a Signed ranks test as the changes, even after log-
arithmic transformation, were not normally distributed.
All p-values were two-tailed, and p < 0.05 was considered to be
signiﬁcant.3. Results
3.1. Cross-sectional analysis of the association of BCP
double mutations and viral loads
Baseline viral loads in the various subgroups are
shown in Table 1. Without adjustment for other factors,
signiﬁcantly lower viral loads were seen in those with tri-
ple mutations at nt 1753 (T? V), 1762 (A? T) and
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between nt 1809 and 1817 (p = 0.03) and in those with
preC stop mutations (nt 1896) (p = 0.0001). There was
a marginally non-signiﬁcant trend towards lower viral
loads in those with BCP double mutations (1762/1764,
p = 0.06). Furthermore, viral loads were higher in those
who were HBeAg positive (p = 0.0001). After control-
ling for HBeAg status, viral loads remained signiﬁcantly
lower in those with BCP double mutations and preC
stop mutations (see Table 2), but the apparent associa-
tions with triple mutations (nt 1753, 1762 and 1764)
and mutations between nt 1809 and 1817 became non-
signiﬁcant. There were no consistent signiﬁcant associa-
tions between viral load and any of the other parameters
considered, including age, sex and viral genotype. Of
note, among the individuals analysed, only three had tri-
ple mutations at 1762 (A? T), 1764 (G? A) and 1766
(C? T) and two had quadruple mutations at 1753
(T? V), 1762 (A? T), 1764 (G? A) and 1766
(C? T). Thus, the numbers of such individuals are
too small to reach any meaningful conclusions about
the independent impact of multiple mutations on viral
loads.
When the analyses were stratiﬁed according to
HBeAg status, the association with BCP double muta-
tions appeared to be much stronger in those who were
HBeAg positive than those who were HBeAg negative.
A formal interaction test (p = 0.004) conﬁrmed that
the eﬀect of BCP double mutations diﬀered between
those who were HBeAg positive and negative. In partic-
ular, whilst there was strong evidence of lower viral
loads among HBeAg positive individuals with BCP dou-
ble mutations than those without these mutations, noTable 2
Results from multivariable regression analyses.
Eﬀect of each
parameter on the
mean viral load
(after log
transformation)
Standard
error
p-value
All study subjects
HBeAg positive 2.38 0.21 0.0001
BCP double mutations
present
0.54 0.18 0.003
preC stop mutations
present
0.58 0.24 0.02
anti-HBe positive (n = 99)
BCP double mutations
present
0.01 0.30 0.96
preC stop mutations
present
0.48 0.31 0.12
HBeAg positive (n = 91)
BCP double mutations
present
1.05 0.18 0.0001
preC stop mutations
present
0.11 0.60 0.86such association was present among those who were
HBeAg negative. In contrast, although the impact of
preC mutations on viral loads appeared to diﬀer
between those who were HBeAg positive and negative
(and were not signiﬁcant in these two subgroups) there
was no signiﬁcant interaction (p = 0.26) between the
two factors, suggesting no evidence that the eﬀect dif-
fered between the two groups.
3.2. Three-year longitudinal analysis of the association of
BCP double mutations and viral loads
Of those who were HBeAg positive, 13 subjects with
BCP double mutations and 9 without were included in
the longitudinal analysis; of those who were HBeAg
negative, 17 and 19 subjects were in the two subgroups,
respectively. The medians of the viral loads for both the
BCP wild-type and BCP double mutations subgroups
are higher in the HBeAg positive group than the anti-
HBe positive group over 3 years. In the HBeAg positive
group, viral loads were signiﬁcantly lower in the BCP
double mutations subgroup than the wild-type subgroup
at months 0, 12, 24 and 36 (p = 0.02, 0.001, 0.04 and
0.008 at each timepoint, respectively). However, in the
anti-HBe positive group, there were no signiﬁcant diﬀer-
ences in the viral loads of the BCP double mutations and
BCP wild-type subgroups at the same timepoints
(p = 0.61, 0.25, 0.61 and 0.12, respectively; Table 3
and Fig. 1).
3.3. Association of BCP double mutations and viral loads
before and after HBeAg seroconversion in individuals
without evolution of the BCP
Seventeen individuals (11 with BCP double muta-
tions, 6 with wild-type BCP) contributed to the analysis
of changes in viral loads before and after HBeAg sero-
conversion. All samples were taken in July or January
of each year; thus, the pre-seroconversion sample would
be expected to be on average 3 months prior to serocon-
version (although the minimum time from seroconver-
sion would be 1 day and the maximum 6 months) and
the post-seroconversion sample would be expected to
be taken on average 3 months after seroconversion (with
a range of 1 day to 6 months, as above). Overall, there
was a signiﬁcant decrease in viral load from pre- to
post-HBeAg seroconversion; whilst this decrease was
signiﬁcant in both subgroups, it was signiﬁcantly greater
in the group that did not have BCP double mutations
(p = 0.03, Mann-Whitney U test). As a result, whilst
viral loads were signiﬁcantly lower prior to HBeAg sero-
conversion in those with BCP double mutations than
those without these mutations (p = 0.01), the diﬀerences
between the two groups were no longer signiﬁcant after
loss of HBeAg (p = 0.27) (Fig. 2). This suggests that,
whilst BCP double mutations are associated with lower
Table 3
Longitudinal analysis of HBV double mutations and HBeAg status and viral loads.
Groups No. Viral loads
Month 0 Month 12 Month 24 Month 36
Median (range) Median (range) Median (range) Median (range)
HBeAg (+)
1762/1764: wild-type 13 2.8  108
(3.0  106, 9.0  109)
2.0  108
(2.0  107, 1.5  109)
2.5  108
(2.2  105, 1.3  109)
2.8  108
(6.3  106, 1.3  109)
1762/1764: mutant 9 1.5  107
(2.2  104, 4.5  108)
1.7  107
(8.0  105, 5.2  108)
2.5  107
(3.2  105, 1.9  108)
3.3  107
(2.5  105, 3.6  108)
p-valuea 0.02 0.001 0.04 0.008
anti-HBe (+)
1762/1764: wild-type 17 8.5  104
(2.8  102, 1.5  108)
7.7  104
(6.4  102, 5.0  107)
1.2  104
(7.8  101, 8.5  105)
1.8  104
(1.3  102, 6.8  105)
1762/1764: mutant 19 8.1  104
(4.9  102, 2.0  109)
3.7  104
(3.8  102, 4.4  106)
1.4  104
(5.2  101, 1.4  106)
4.6  104
(1.2  102, 2.0  108)
p-valuea 0.61 0.25 0.61 0.12
a p-Value obtained from unpaired t-test after log transformation.
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eﬀect on the viral loads of HBeAg negative individuals.
3.4. Association of BCP double mutations and viral loads
before and after evolution of BCP double mutations in
individuals without HBeAg or anti-HBe seroconversion
Because evolution of the BCP sequence was observed
only in a few individuals, the number of individuals with
samples available for analysis is too small to reach any
reliable conclusions. However, it is clear that all viral
loads decline after evolution of the BCP sequence from
wild-type to double mutations in individuals who
remained HBeAg positive after the mutations were
detected. However, viral loads may decline or increase
after evolution of BCP mutations in individuals who
remained HBeAg negative (Table 4). These results also
suggest that BCP double mutations have no eﬀect onFig. 1. Longitudinal analysis of viral loads according to BCP double
mutations and HBeAg status. The box plot shows median values, upper
and lower quartiles and the largest and smallest observations.viral loads in anti-HBe positive individuals but determi-
nation of their eﬀect in HBeAg positive individuals
requires further study.4. Discussion
The principal ﬁnding of this study is that BCP double
mutations are associated with lower viral loads in
HBeAg positive individuals but have no eﬀect on the
viral loads of anti-HBe positive individuals. Other muta-
tions in the BCP and the major precore mutation at nt
1896 are not associated with viral loads. The strength
of this study is that the cross sectional analysis is sup-
ported by a long-term longitudinal analysis, which over-
comes the deﬁciencies associated with ﬂuctuations of
viral loads, especially around the time of seroconversion
of HBeAg. The weakness of the study is the limitation of
sample size. Although the double mutations do not pre-
vent the synthesis of HBeAg, they suppress its levels
[2,7,8], so that samples with both HBeAg positive and
BCP double mutations are uncommon. We do not have
suﬃcient numbers in the cohort for the subgroup of
females who are HBeAg positive and have BCP double
mutations and this prevented us from including suﬃ-
cient numbers for the stratiﬁcation analysis and answer-
ing completely all of the questions posed initially. There
were very few individuals with evolution of the BCP
without HBeAg seroconversion, so that a statistically
signiﬁcant conclusion could not be reached, although
the limited number of samples available provides evi-
dence of little eﬀect on viral loads.
Reports of the association of BCP double mutations
with virus replication have reached conﬂicting conclu-
sions: increased virus replication [2,7,8], no eﬀect on
virus replication [9–12,15,24] or reduced virus replica-
tion [13], and it is not clear which conclusion is reliable.
Fig. 2. Pre- and post-HBeAg seroconversion vviral loads, stratiﬁes by
the presence of BCP double mutations, among 17 individuals without
BCP evolution.
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DNA into cells in culture but virus replication in vitro
diﬀers from that in vivo, where it is inﬂuenced by the
interaction of virus with the complex host immune sys-
tem. The eﬀect of BCP double mutations on virus repli-
cation in vitro may not be representative of the situation
in vivo [25]. Although other studies are based on clinical
samples, they all involve cross-sectional analysis and
viral loads may ﬂuctuate over time [19]. In addition,
seroconversion from HBeAg to anti-HBe, either sponta-
neous or after antiviral therapy, usually indicates lower
viral loads. This decline may occur up to one year before
HBeAg seroconversion [18]. One measurement, or mea-
surements made close to seroconversion of HBeAg, may
not be ideal for evaluating the eﬀect of BCP double
mutations on viral loads. This study included not only
a cross-sectional analysis but also a long-term longitudi-
nal analysis. Therefore, the results are more reliable than
previous studies.
The natural course of chronic HBV infection can be
divided into four phases based on the virus–host interac-Table 4
Evolution of BCP and viral loads, without HBeAg seroconversion.
Samples Sex Age BCP 1a BCP 2b H
GA070 F 30 WT DM +
JS19 F 30 WT DM +
TJ163 M 36 WT DM +
YF163 F 30 WT DM +
NX109 M 35 WT DM +
CZ041 M 35 WT DM –
DD928 F 37 WT DM –
GM256 M 30 WT DM –
TW215 M 45 WT DM –
TM334 F 31 WT DM –
a WT: BCP wild-type.
b DM: BCP double mutations.tion: immune tolerance, immunoreactive, low or non-
replication, and reactivation. Virus replication proceeds
at very high levels in immune tolerance phase, while
HBV DNA levels ﬂuctuate, but decreases progressively
in the second, immunoreactive phase. HBeAg remains
positive until clearance by the immune system at the
end of the second phase. The third phase is characterised
by undetectable HBeAg and anti-HBe positivity, with
undetectable or low levels of HBV DNA [26]. It has
been suggested that BCP double mutations may be
selected through CTL escape when immune tolerance
is lost and HBeAg concentrations are falling [27]. It
may be postulated that, among individuals who are
positive for HBeAg, those with wild-type and mutant
BCP sequences are in diﬀerent phases of infection, the
former being in the ﬁrst phase and the latter, at the
end of second phase. They experience diﬀerent immune
pressure, resulting in diﬀerent levels of virus replication.
However, those who are HBeAg negative, regardless of
BCP sequence, are in the same phase (the third phase)
and experience similar immune pressures, resulting in
similar levels of virus replication. If this is the case, it
is not diﬃcult to understand why BCP double mutations
are associated with lower viral loads in HBeAg positive
individuals but have no eﬀect in HBeAg negative
individuals.
It has been suggested that BCP double mutations are
associated with the development of HCC [28–33] and
this ﬁnding has been conﬁrmed recently by our prospec-
tive cohort study [20]. However, the mechanisms of
oncogenesis remain obscure. Although we hypothesized
originally that BCP double mutations result in an
increase in the levels of replicative intermediates and,
consequently, of integration events [29], the results of
this study do not support this hypothesis and suggest
that the association of BCP double mutations with the
development of HCC is not attributable to increased
viral DNA replication. In addition, it has been postu-
lated that fulminant liver failure may be the result of
increased virus replication resulting from the BCP muta-
tions, which may upregulate pregenomic RNA, withBeAg 1 HBeAg 2 Viral loads 1 Viral loads 2
+ 2.23  107 9.54  106
+ 3.27  108 2.47  108
+ 3.66  108 1.48  108
+ 3.80  108 1.23  108
+ 2.46  108 1.60  108
– 9.18  105 1.42  107
– 1.83  104 96.55
– 5.80  107 3.29  108
– 2.79  105 3.92  106
– 402.61 94.44
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[15]. Again, our results do not support this postulate.
The association of other combinations of mutations,
such as the triple core promoter mutations 1753/1762/
1764, and viral loads remain uncertain. Huang et al.
[34] suggested that these triple mutations are associated
with lower HBV viral loads but others claim that they
increase viral loads [14,15]. We found there is no corre-
lation of this combination of mutations with viral loads.
Although mutations at nt 1766 and 1768 have been sug-
gested to be associated with increased virus replication
[14,15], these mutations are rare in our cohort (3 in
190 at nt 1766 and none in 190 at nt 1768). Mutations
at nucleotide 1809–1817 may be associated with lower
HBV viral loads [34] but this is not clear from the pres-
ent study. A report from Hong Kong show that the
major precore stop mutation is associated with lower
viral loads [8] while there was no correlation between
the presence of the mutation and HBV DNA levels in
a Korean study [12]. The data presented here support
the latter conclusion.
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